Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00994188
Other study ID # TW062090617KT
Secondary ID
Status Recruiting
Phase N/A
First received October 9, 2009
Last updated October 13, 2009
Start date July 2009
Est. completion date June 2014

Study information

Verified date October 2009
Source Tokushukai Medical Group
Contact Yoshihide Ogawa, MD, PhD
Phone +81-42-500-4433
Email transplant-office@tokushukai.jp
Is FDA regulated No
Health authority Japan: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Approximately 30,000 new patients are introduced into dialysis and about 20,000 of them die every year in Japan. At present, about 300,000 patients are on dialysis and more than 10,000 patients are registered with the Japan Organ Transplant Network (JOTN) with the hope for a renal transplantation. If the renal function is restored by transplantation, the quality of life (QOL) improves and more than 90% are reportedly comeback to their normal life activities and get relieved from the burden of dialysis. Furthermore, it can reduce the dialysis related medical cost by as much as 50%. However, only about 1,000 renal transplantation cases are annually carried out in Japan. Among them, 80-85% are living renal transplantations offered by family members or relatives, and the rest are from deceased donors.

Due to the fact that the number of deceased donors are scarce and only living renal transplantations between the family members or relatives are currently allowed in Japan, the approximate waiting time to receive a renal transplantation is 16 years. For that reason, many patients travel abroad to receive a renal transplantation.

There are reports that total nephrectomies are performed as a treatment for small size (4 cm or less) renal tumors, renal stones, ureteral tumors and ureteral strictures in many cases and that many of these nephrectomized kidneys can be successfully transplanted after surgical restoration with satisfactory results. However, due to the lack of necessary evidence it is currently not allowed in Japan.

Therefore, the investigators planned the present clinical study to evaluate the curative efficacy (renal function, QOL) and safety (side effects, complications or occurrence of renal cancer) of living renal transplantations between family members and relatives with restored donor kidneys after the surgical removal or repairment of a small size (4 cm or less) renal tumor or renal stone, ureteral tumor or ureteral stricture, in order to acquire necessary clinical data for potential enrichment of the renal donor pool in Japan as well as to develop useful medical care for our patients who are on dialysis for many years due to the renal failure.


Recruitment information / eligibility

Status Recruiting
Enrollment 5
Est. completion date June 2014
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender Both
Age group 20 Years and older
Eligibility Inclusion Criteria:

A) Recipient:

- Patients who are suffering from renal failure and are willing to receive a restored kidney from a family member

- Patients who are eligible for general anesthesia

- Patients who have given written informed consent to participate in the study

B) Donor:

- Potential donors who are incidentally diagnosed with small renal tumor (size: <4 cm) or renal stone, ureteral tumor or ureteral stricture and have permitted to transplant the kidney to a family member upon its surgical restoration

- Patients who are eligible for general anesthesia

- Patients who have given written informed consent to participate in the study

Exclusion Criteria:

A) Recipient:

- Patients who have infectious disease, hemorrhagic ulcer, or malignant cancer

- Patients who have serious vascular lesions (eg. arteriosclerosis, thromboembolic disease) and are currently on treatment

- Patients who were disapproved by the Institutional Ethics Committee

B) Donor:

- Patients who have tested positive for serious infectious disease (eg. HIV, HBV, or HCV)

- Patients who were diagnosed with malignant lymphoma or sarcoma

- Patients who were on chemotherapy or radiation therapy for renal cancer prior to the nephrectomy

- Patients who were disapproved by the Institutional Ethics Committee

(*) Other inclusion/exclusion criteria defined in the protocol for both recipient and donor may apply.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Procedure:
Restored Kidney Transplant Between Family Members
Tumor part of the kidney or ureter and ureteral stricture is surgically removed or repaired and the kidney is restored and transplanted to a family member recipient

Locations

Country Name City State
Japan Tokyo-West Tokushukai Hospital Transplant Office Akishima City Tokyo
Japan Uwajima Tokushukai Hospital Uwajima Ehime

Sponsors (1)

Lead Sponsor Collaborator
Tokushukai Medical Group

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of curative efficacy (renal function and QOL) and safety (side effects, complications) after renal transplantation with restored kidneys between family members 12 Months Yes
See also
  Status Clinical Trial Phase
Completed NCT05990660 - Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery N/A
Recruiting NCT04096547 - Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment
Completed NCT04024332 - Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects Phase 1
Completed NCT02849964 - Factors Related to Geographical Variation in the Incidence of End-stage Renal Failure: An Analysis in 5 French Regions N/A
Active, not recruiting NCT03672110 - Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen Phase 3
Completed NCT01462136 - PK Study of ACHN-490 Injection in Renally Impaired Subjects Phase 1
Completed NCT01407874 - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency Phase 2
Completed NCT01172431 - Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency Phase 4
Completed NCT00765830 - Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension) Phase 3
Completed NCT01545531 - Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance N/A
Completed NCT00770081 - Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study) Phase 3
Terminated NCT00338455 - Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC Phase 2
Completed NCT00159614 - Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment Phase 2
Completed NCT02894905 - A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335 Phase 1
Completed NCT02894385 - Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201) Phase 1
Active, not recruiting NCT04876963 - HOLT-ED: Holter-monitoring in End-stage Renal Disease
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Completed NCT03235375 - A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects Phase 1
Withdrawn NCT03329612 - Remote Ischemic Preconditioning in ACS Patients N/A
Recruiting NCT02578784 - DEB-after-Cutting Balloon-PTA in Dialysis Fistula Stenosis N/A